A near fatal case of the dapsone hypersensitivity syndrome in a patient with urticarial vasculitis

Clinical and Experimental Dermatology

Volumn 28, Issue 5, 2003, Pages 496-498

  Leslie, K S ^a   Gaffney, K ^a   Ross, C N ^a   Ridley, S ^a   Barker, T H ^a   Garioch, J J ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CROTAMITON; DAPSONE; FOLINIC ACID; HYDROCORTISONE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE;

ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DAPSONE HYPERSENSITIVITY SYNDROME; DISEASE COURSE; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; FATALITY; FEMALE; FEVER; HEADACHE; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; INTENSIVE CARE; LABORATORY TEST; LETHARGY; LIVER DYSFUNCTION; LYMPHOCYTOSIS; METHEMOGLOBINEMIA; PATIENT; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT OUTCOME; URTICARIA; VASCULITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DAPSONE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MIDDLE AGED; NECROSIS; URTICARIA;

EID: 0042911950     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2003.01336.x     Document Type: Article

References (13)

1. Johnson B. Benign familial chronic pemphigus treated with dapsone. J Natl Med Assoc 1972; 64: 326-7.
2. Person JR, Rogers RS III Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977; 113: 610-5.
3. Thompson DM, Heaf PJ, Robinson TW. Australia antigen polyarteritis treated with prednisone and dapsone. Proc Roy Soc Med 1976; 69: 389-90.
4. Wells GC. Allergic vasculitis (tri-symptom of Gougerot) treated with dapsone. Proc Roy Soc Med 1969; 62: 665-6.
5. Millikan LC, Harrell ER. Drug reactions to the sulfones. Arch Dermatol 1970; 102: 220-4.
6. Mohamed KN. Hypersensitivity reaction to dapsone: report from Malaysia. Lepr Rev 1984; 55: 385-9.
7. Booth SA, Moody CE, Dahl MV et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98: 135-40.
8. Huong-Nguyen V, Kadunce DP, Hendrix JD et al. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 1993; 100: 349-55.
9. Lowe J. Treatment of leprosy by diamine diphenyl sulfone by mouth. Lancet 1950; 1: 145-50.
10. Johnson DA, Cattau EL Jr, Kuritsky JN, Zimmerman HJ. Liver involvement in the sulfone syndrome. Arch Intern Med 1986; 146: 875-7.
11. Mohle-Boetani J, Akula SK, Holodniy M, Katzenstein D, Garcia G. The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia. West J Med 1992; 156: 303-6.
12. Sherlock S. Hepatic reactions to therapeutic agents. Annu Rev Pharmacol Toxicol 1965; 5: 429-46.
13. Sherlock S. Prediction of hepatotoxicity due to therapeutic agents in man. Medicine (Baltimore) 1966; 45: 453-8.